GlassScriptPhysician profile
Leonard K Baidoo
NPI 1669444642
$152,471.17
in general payments reported to CMS, 2019-2025
19 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,155 · 2021: $330 · 2022: $17K · 2023: $37K · 2024: $43K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $17K · Travel and Lodging: $10K · Food and Beverage: $6,145 · Education: $12.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,474.00 |
| Consulting Fee | $16,500.00 |
| Travel and Lodging | $10,348.44 |
| Food and Beverage | $6,145.44 |
| Education | $12.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $52,890.84 | 2021-2024 | Zeposia |
| Pfizer INC. | $46,942.25 | 2019-2025 | |
| Janssen Biotech, INC. | $23,985.49 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $22,191.00 | 2024-2025 | Omvoh |
| Celgene Corporation | $3,810.37 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $608.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $592.01 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $389.35 | 2024-2025 | Entyvio, Gattex |
| Abbvie INC. | $232.68 | 2022 | |
| Medtronic, INC. | $184.08 | 2022 | |
| Boston Scientific Corporation | $145.74 | 2025 | Spyglass |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.42 | 2025 | |
| Intercept Pharmaceuticals, INC. | $70.78 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $70.67 | 2025 | Vegzelma |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $62.80 | 2024 | Eus Needles, Eyemax, Forceps |
| Gilead Sciences, INC. | $29.91 | 2021 | |
| Novo Nordisk INC | $15.94 | 2025 | Wegovy |
| Capsovision, INC. | $15.75 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Baidoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.